You are here: Industry Insights > Crohn's disease

News List

What Diet Is Most Likely to Help Ease Crohn's Disease? drugs
June 09, 2021
People who have Crohn's disease often seek to ease their symptoms by changing what they eat, and new research suggests the Mediterranean diet may be their best bet.
First Patient Dosed in Phase 2a Sibofimloc Trial for Crohn's disease americanpharmaceuticalreview
September 30, 2020
ENTEROME announced the first patient has been dosed in a Phase 2a clinical trial of sibofimloc (EB8018/TAK-018) in patients with Crohn's disease.
Stero Biotechs to Commence Phase 2a Trial of Cannabidiol-Based Formulation for Crohn's Disease americanpharmaceuticalreview
July 24, 2019
Stero Biotechs received its second Helsinki approval to move forward with a second Phase 2a clinical trial. The trial will be a randomized, double-blind, placebo-controlled, multicenter study of ST-SDCD-01 ...
Theravance Biopharma Announces First Patient Dosed in Phase 2 Study of TD-1473 in Patients with Crohn's Disease pharmafocusasia
November 26, 2018
Theravance Biopharma, Inc. announced dosing of the first patient in a Phase 2 clinical trial of TD-1473 in patients with Crohn's disease...
Arena 3 for 3 as Crohn’s drug meets proof-of-concept test fiercebiotech
September 27, 2018
The data shows that olorinab warrants further development, an analyst says.
iCAN, Yom Chai signs MoU for crohn's disease and autism biospectrumasia
August 22, 2018
Yom Chai, in collaboration with leading American and Israeli scientists and medical professionals is initially developing a formulated suppository targeting people...
Celgene Takes a $411M Hit From Discontinuation of Crohn's Disease Trials biospace
January 02, 2018
Celgene announced back in October that it was discontinuing its GED-0301 (mongersen) program for Crohn’s disease. Now Celgene has worked out how much that decision is costing the company—$411 million.
RedHill Biopharma Announces Unanimous Positive DSMB Recommendation for Continuation of the Phase III b3cnewswire
August 01, 2017
RedHill Biopharma Ltd. reported that it has received a unanimous positive recommendation from the DSMB to continue the study as planned.
Janssen Biotech, Protagonist in Exclusive PTG-200 Pact contractpharma
May 31, 2017
To develop, manufacture and commercialize PTG-200 for Crohn's disease and ulcerative colitis
New Real-World Analyses Support Effectiveness and Safety of Entyvio(R) (vedolizumab) for Ulcerative en-cphi.cn
May 09, 2017
Data showcased at Digestive Disease Week (DDW) 2017 meeting include presentations of new analyses from the VICTORY consortium

Previous page 1 2 Next page